Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 5/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | PIP5K1C | O60331 | 12/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.41 |
| ▸ | PIP5K1B | O14986 | 3/20 | 0.39 |
| ▸ | PIP5K1A | Q99755 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PI4KA | P42356 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836435 | 1.00 | MAPK10 (0.43) | MAPK10MAPK8MAPK14GSK3BPIP5K1C | |
| SCHEMBL29836417 | 0.95 | GSK3B (0.47) | MAPK14GSK3B | |
| SCHEMBL21591765 | 0.95 | GSK3B (0.47) | MAPK14GSK3B | |
| SCHEMBL21591782 | 0.92 | GSK3B (0.43) | MAPK14GSK3B | |
| SCHEMBL29836423 | 0.92 | GSK3B (0.43) | MAPK14GSK3B | |
| SCHEMBL21593202 | 0.89 | MAP4K1 (0.37) | GSK3BPIP5K1CPIK3CA | |
| SCHEMBL29836563 | 0.85 | ROCK2 (0.38) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL21591758 | 0.85 | ROCK2 (0.38) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL21593250 | 0.83 | BRAF (0.36) | GSK3B | |
| SCHEMBL29836438 | 0.83 | BRAF (0.36) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | claimed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | claimed |
| EP-3807273-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2021-04-21 | — | — | EP | claimed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | claimed |
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | MAPK10 521/4885MAPK8 981/4885MAPK14 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.